Efficacy and safety of pyrotinib-based regimens in patients with HER2-positive stage III/IV breast cancer: a real-world retrospective study in China

Background Data from multiple clinical trials have shown that pyrotinib has demonstrated significant efficacy and acceptable tolerability in patients with HER2-positive advanced breast cancer (BC). However, the short time to market in China limits our comprehensive understanding of the drug’s long-t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Limin Zhi, Lei Huang, Xiaohong Pang, Qiong Wu, Yu Lei
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	PeerJ Inc. 2026-01-01
Edice:	PeerJ
Témata:	Pyrotinib HER2-positive breast cancer Stage III/IV Efficacy Safety Real-world study
On-line přístup:	https://peerj.com/articles/20524.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!